Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
Author:
Publisher
Elsevier BV
Subject
Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy
Reference10 articles.
1. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial;Christopoulos;BMC Nephrol,2009
2. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries;Getahun;Eur Respir J,2015
3. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection;Sandul;Clin Infect Dis,2017
4. Three months of rifapentine and isoniazid for latent tuberculosis infection;Sterling;N Engl J Med,2011
5. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study;Sterling;Clin Infect Dis,2015
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diabetes and TB: Confluence of Two Epidemic and Its Effect on Clinical Presentation;Current Diabetes Reviews;2024-01
2. Chapitre 6: Le traitement préventif de la tuberculose chez les adultes;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02
3. Effect of replacement therapy (CRRT) and hemodialysis (IHD) on severe acute renal failure;Frontiers in Pharmacology;2023-07-21
4. Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection;Tropical Medicine and Infectious Disease;2023-01-28
5. Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial);PLOS ONE;2022-10-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3